Navigation Links
The International Myeloma Foundation Says New Clinical Trial,Results Could Improve Survival While Reducing Side Effects For Many,Patients

the IMF, added, "These findings may also have wider implications for cancer treatments because they challenge the traditional notion that patients should be treated with the highest dose of medicine they can tolerate. Now we have evidence that in some situations, less may be more when treating cancer."

REVLIMID from the Celgene Corporation is the newest of the group of medicines called novel therapies that have significantly improved the outlook for patients with myeloma. Preliminary analysis of the ECOG data shows patients taking REVLIMID plus low dose dexamethasone had a 96% survival rate after one year with a reduced risk of side effects. One year survival for those taking the higher dose of dexamethasone was 86%. The findings are expected to prompt review of the dexamethasone dose when paired with other medications used in myeloma such as THALOMID(R), and discussions are already underway to change dosing in other clinical trials using REVLIMID with dexamethasone.

"This is a very exciting finding for patients," said Michael Katz, who, as a 16-year myeloma survivor, is a vice president of the IMF and co-chair of ECOG's Patient Representatives Committee. "When ECOG's patient representatives proposed adding a lower dose 'dex' arm to this trial, we were just looking for a way to make the treatment more tolerable; we never expected that the outcome for patients would actually improve. We are grateful to all of the patients who participated and to ECOG Group chair, Dr. Robert Comis and Myeloma Committee chair, Dr. Vincent Rajkumar, for supporting the notion of testing lower doses and making this trial happen."

Mr. Katz continued: "This result sends an important signal to physicians that maximum tolerated dose is not always the right answer when treating patients with cancers like myeloma that are incurable, but highly treatable."

Myeloma, also called multiple myeloma, is a cancer of the bone marrow that affects production of red cells, white
'"/>




Page: 1 2 3

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
6. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
7. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
8. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
9. Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine
10. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
11. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
Post Your Comments:
(Date:5/22/2013)... May 22, 2013 Advanced Prenatal Therapeutics (APT), ... that will help alleviate the high blood pressure and ... is expected to be the first medical device specifically ... and fetal death. Every year, preeclampsia affects ... States . It is characterized by high blood ...
(Date:5/22/2013)... May 22, 2013 Attorney Advertising -- Bronstein, ... on behalf of purchasers of the securities of ... AMAG -News).  The investigation focuses on whether the ... On May 22, 2013, Shares of ... after the company announced in regulatory filing that ...
(Date:5/22/2013)... , May 22, 2013  The Leukemia & Lymphoma ... to Valor Biotherapeutics, LLC, a joint venture between ImmunGene ... manufacturing, and a Phase I clinical trial for a ... faced by many patients with indolent lymphomas who do ... Valor,s protein, IGN002, is a new class of ...
Breaking Medicine Technology:Advanced Prenatal Therapeutics - Using Targeted Apheresis to Treat Preeclampsia 2Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AMAG Pharmaceuticals, Inc. 2The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 2The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 3The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 4
... PARSIPPANY, N.J., Jan. 31, 2011 PDI, Inc. (Nasdaq: ... officer, is scheduled to present at the UBS 21st Annual Global ... at the Grand Hyatt New York. The live ... company,s website at http://www.pdi-inc.com . The webcast will be archived ...
... Calif., Jan. 31, 2011 OXIS International, Inc., (OTC ... today announced highly favorable final results from an initial ... patent-pending ERGOFLEX™ joint health formula, launched commercially ... of pain was statistically significant after as little as ...
Cached Medicine Technology:Final Results from ERGOFLEX Study Show Statistically Significant Reduction in Joint Pain in as Little as One Week 2Final Results from ERGOFLEX Study Show Statistically Significant Reduction in Joint Pain in as Little as One Week 3Final Results from ERGOFLEX Study Show Statistically Significant Reduction in Joint Pain in as Little as One Week 4
(Date:5/22/2013)... that bicyclists who wear helmets have an 88 percent ... Children,s Hospital found that simply having bicycle helmet laws ... and injuries for children younger than 16 who were ... study, conducted by William P. Meehan III, MD, Lois ... of Boston Children,s Hospital, and Christopher M. Fischer, MD, ...
(Date:5/22/2013)... MD (PRWEB) May 22, 2013 On a ... Lisa, spent a few hours watching “The Bourne Legacy” at ... While this may seem like a typical activity to many ... This little stretch of respite from their everyday reality has ... Seals Serving DC | MD | VA. , Life changed ...
(Date:5/22/2013)... The Muscular Dystrophy Association scored a huge ... annual Charlotte Muscle Team event held May 21 by ... with muscle disease. , "The Charlotte community really ... families,” said MDA Divisional Director Theresa Miller. “From the ... "Buddy" to make their night extra special, to the ...
(Date:5/22/2013)... Reporter , , WEDNESDAY, May 22 (HealthDay News) -- People ... likely to attempt suicide, whether or not they also ... a new study. "Clinicians who are seeing patients ... at increased risk of suicide," said study co-author Mark ... Resource and Evaluation Center in Ann Arbor, Mich. ...
(Date:5/22/2013)... Cedar Rapids, IA (PRWEB) May 22, 2013 ... inspirational theatre piece Handicap This! The performance promotes ... pursuing their dreams. The Handicap This! performance will be ... Linn Mar High School auditorium. Tickets for Handicap ... , Handicap This! helps audiences measure the level to ...
Breaking Medicine News(10 mins):Health News:Rate of bicycle-related fatalities significantly lower in states with helmet laws 2Health News:Military Family Finds Respite with Easter Seals 2Health News:Military Family Finds Respite with Easter Seals 3Health News:Charlotte Muscle Team Event Raises $300,000 in the Fight Against Muscle Disease 2Health News:Migraine, Chronic Back Pain Tied to Higher Suicide Risk 2Health News:Migraine, Chronic Back Pain Tied to Higher Suicide Risk 3Health News:Handicap This! Comes to Marion, Iowa 2
... ... ... Advocate Christ Medical Center and Hope Children’s Hospital was awarded the Morehead Apex Workplace ... the Ritz-Carlton in Charlotte, N.C. , , ,Christ Medical Center and Hope Children’s Hospital ...
... lead to new birth control for men , WEDNESDAY, April ... proteins called PLA2s play a vital role in sperm function ... The findings could improve understanding of male infertility and lead ... infertility. , In one study, Japanese researchers found that the ...
... ... except if the girls in the salon chair are battling cancer or other serious illness. Then, ... ... at the Tipperary Hair Salon in Beverly Hills, California, approximately 35 such girls and their sisters ...
... ... District to Develop a 100 Percent Lead Free Bubbler Retrofit Kit , ... Los Angeles, CA (Vocus) April 28, 2010 -- ... and chillers and a division of Acorn Engineering Company, announces a 100 percent lead-free bubbler ...
... 28, 2010 Many of the world,s leading experts in ... first-of-its-kind conference in Kansas City to change the way childhood ... hosted by Children,s Mercy Hospitals and Clinics, is to apply ... unique make-up of pediatric patients and improve outcomes. ...
... ... about supporting you after the sale when you believe you need to return an item. ... with complete confidence knowing that their purchase can be returned for a replacement or a ... ...
Cached Medicine News:Health News:Advocate Christ Medical Center Presented The 2009 Morehead Apex Workplace of Excellence Award 2Health News:Advocate Christ Medical Center Presented The 2009 Morehead Apex Workplace of Excellence Award 3Health News:Pediatric Patients and Siblings Enjoy Beverly Hills Beauty Makeover 2Health News:Pediatric Patients and Siblings Enjoy Beverly Hills Beauty Makeover 3Health News:The Acorn Aqua's Lead Free Bubbler 2Health News:Advances in personalized medicine take center stage 2Health News:National Allergy Supply, The Allergy Products Company Recommended By More Than 9,500 Doctors Nationwide, Announces 100% Unconditional Satisfaction Guarantee 2
... wide range of miniTHERM incubators is available, ... application solution for their specific requirements. miniTHERM ... are compact and extremely space saving. Their ... oven. It is possible to stack up ...
... range of miniTHERM incubators is available, ensuring ... solution for their specific requirements. miniTHERM incubators ... compact and extremely space saving. Their size ... It is possible to stack up to ...
... resistance of stainless steel with the ... offers an electro-polished copper-alloy-stainless interior that ... sterile environment promotes the integrity of ... safety of laboratory staff. This exclusive ...
US Autoflow Single Chamber Stackable Water-Jacketed CO2 Inc.w/ Humidity Display and Control...
Medicine Products: